Subjective cognitive complaints
Conditions
Interventions
Group 1: Pharmacy customers and patients aged 60 or older reporting cognitive complaints in urban and rural community pharmacies in the Munich area, Germany, will be included. On-site digital screenin
SCD-Q17), depressive symptoms (Center for Epidemiologic Studies Depression Scale
CES-D-10), and cardiovascular risk factors (Mansoor Self-Report Cardiovascular Disease Risk Questionnaire).
Based on the screening results, trained pharmacy staff provide individualized feedback (step
Sponsors
LMU Klinikum München, Klinik für Psychiatrie und Psychotherapie
Eligibility
Sex/Gender
All
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: - Pharmacy customers or patients of age =60 years and of any sex or ethnicity - Presence of subjective cognitive decline = Operationalized as a positive response to at least one of the three initial questions of the Subjective Cognitive Decline Questionnaire (SCD-Q17) - Ability to understand study procedures and to provide written informed consent, as judged appropriate by the pharmacists/pharmaceutical staff.
Exclusion criteria
Exclusion criteria: - Prior diagnosis of dementia (with or without supporting pathological evidence) as documented in medical records or confirmed by a physician - Insufficient proficiency in the German language - Significant visual impairments - Significant fine motor skill disorders.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome of the study is participants’ quality of life (QoL), assessed at three time points: at the initial screening (T1, baseline), 12 months after screening (T2), and 24 months after screening (T3). QoL is assessed with the 13-item Older People’s Quality of Life – Brief questionnaire (OPQOL-brief), which covers well-being, health, social relationships, independence, home environment, leisure, and finances. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints include the sociodemographic characteristics of the participants, which are assessed using a questionnaire; healthcare utilization, as well as changes in diagnoses and medication following screening, which are evaluated at least at two time points (12 months and 24 months after screening) through structured telephone interviews. In addition, the acceptance and feasibility of the screening are examined using a qualitative, exploratory approach. | — |
Countries
Germany
Contacts
Public ContactRobert Perneczky
LMU Klinikum, Klinik für Psychiatrie und Psychotherapie
Outcome results
None listed